1-cyclopropylpyrrolidin-2-one | 33872-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-cyclopropylpyrrolidin-2-one
• 英文别名: N-cyclopropylpyrrolidone
• CAS: 33872-24-1
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: AICZMNWUKVFBFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-吡咯烷酮 、 环丙基硼酸频哪醇酯 在 吡啶 、 氧气 、 copper diacetate 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以93%的产率得到1-cyclopropylpyrrolidin-2-one
  参考文献：
  名称：

  铜促进的仲无环酰胺的直接N-环丙基化。

  摘要：

  已知是不良亲核试剂的芳香族和脂肪族仲无环酰胺的N-环丙基化已使用简单且廉价的铜系统完成。已经以良好或优异的产率获得了构成广泛的生物活性化合物家族的相应的叔无环酰胺。

  DOI：

  10.1039/c3cc42575d

文献信息

• [EN] BENZAMIDE CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES BENZAMIDES DES RÉCEPTEUR CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2015161011A1

  公开（公告）日：2015-10-22

  The present invention is directed to benzamide compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及苯甲酰胺化合物，其为CGRP受体拮抗剂，用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的用途。
• 10.1038/s41586-024-07628-1
  作者：Boyle, Benjamin T.、Dow, Nathan W.、Kelly, Christopher B.、Bryan, Marian C.、MacMillan, David W. C.

  DOI：10.1038/s41586-024-07628-1

  日期：——

  The ability to tame high-energy intermediates is critical for synthetic chemistry, enabling the construction of complex molecules and propelling advances in the field of synthesis. Along these lines, carbenes and carbenoid intermediates are particularly attractive, but often elusive, high-energy intermediates.1,2 Classical methods to access metal carbene intermediates exploit two-electron chemistry

  驯服高能中间体的能力对于合成化学至关重要，能够构建复杂分子并推动合成领域的进步。沿着这些思路，卡宾和类甲虫中间体是特别有吸引力但通常难以捉摸的高能中间体。1,2 获得金属卡宾中间体的经典方法利用双电子化学形成关键的碳-金属键。然而，由于试剂安全问题，这些方法通常令人望而却步，限制了它们在合成中的广泛实施。3–6从机制上讲，可以避免这些陷阱的卡宾中间体的替代方法将涉及两个单电子步骤：向金属中加入自由基以形成初始碳金属键，然后是氧化还原促进的α消除以产生所需的金属卡宾中间体。在此，该策略是通过 metallaphotoredox 平台实现的，该平台利用现成的化学原料作为自由基源的铁卡宾反应性，并从六类以前未充分利用的离型基团中消除α。这些发现允许从丰度且实验室稳定的羧酸、氨基酸和醇中实现环丙烷化和σ键插入 N-H、S-H 和 P-H 键，从而为卡宾介导的化学多样化挑战提供了通用解决方案。
• NLRP3 MODULATORS
  申请人：Innate Tumor Immunity, Inc.

  公开号：US20190055236A1

  公开（公告）日：2019-02-21

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
• Direct N-cyclopropylation of secondary acyclic amides promoted by copper
  作者：Emilie Racine、Florian Monnier、Jean-Pierre Vors、Marc Taillefer

  DOI：10.1039/c3cc42575d

  日期：——

  The N-cyclopropylation of aromatic and aliphatic secondary acyclic amides, known to be poor nucleophiles, has been accomplished using a simple and cheap copper system. The corresponding tertiary acyclic amides, which constitute a wide family of biologically active compounds, have been obtained in good to excellent yields.

  已知是不良亲核试剂的芳香族和脂肪族仲无环酰胺的N-环丙基化已使用简单且廉价的铜系统完成。已经以良好或优异的产率获得了构成广泛的生物活性化合物家族的相应的叔无环酰胺。